This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Biomarker Analysis and Outcomes in Neoadjuvant Nivo + Relatlimab for Resectable Melanoma

24 views
October 17, 2024
Comments 0
Login to view comments. Click here to Login